Guwahati Mail

DelveInsight’s “Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Ischemic Stroke, historical and forecasted epidemiology as well as the Acute Ischemic Stroke market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Acute Ischemic Stroke market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Ischemic Stroke Market Forecast

Some of the key facts of the Acute Ischemic Stroke Market Report: 

• The Acute Ischemic Stroke market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The World Health Organisation (WHO) estimates that 15 million people worldwide experience a stroke each year. Five million of them pass away, and another five million end up with permanent disabilities
• In July 2022, The European Medicines Agency (EMA) granted “PRIority Medicines” designation to ACTICOR BIOTECH for its therapeutic candidate, glenzocimab, for the treatment of stroke victims.With early conversations with regulatory agencies and strengthened relations as a result of this status, Acticor Biotech was able to reaffirm the clinical development strategy for the treatment of stroke with glenzocimab
• In July 2022, In a groundbreaking preclinical study, the University of Cincinnati and Case Western Reserve University (CWRU) showed that NervGen’s proprietary drug, NVG-291-R, promotes nervous system repair and significant functional recovery in a mouse model of severe ischemic stroke, even when treatment was started up to 7 days after onset. This information was released by NervGen Pharma
• According to the American Stroke Association, ischemic strokes, in which blood flow to the brain is impeded, account for around 87% of all strokes
• Stem cell therapyMultiStem is the most eagerly awaited new product among developing therapeutics. In addition to this, numerous additional compounds, including LT-3001, Glenzocimab, Elezanumab, and others, are in early clinical stage or mid stage research
• Key Acute Ischemic Stroke Companies: Athersys/Healios K.K., Acticor Biotech, Lumosa Therapeutics, Abbvie, Acticor Biotech, GrandPharma, Astellas Pharma, Tasly Biopharmaceuticals, Shanghai Pharmaceuticals, Hoffmann-La Roche, Biogen, Jiangsu Simcere, Lundbeck, Biogen, Dexa Medica Group, Mitsubishi Tanabe Pharma, and others
• Key Acute Ischemic Stroke Therapies: MultiStem, Glenzocimab, LT-3001, Elezanumab, Intravenous glenzocimab (ACT017), Tirofiban, YM872 (zonampanel), Elezanumab, rhPro-UK, LT3001, Balovaptan, Alteplase, DLBS1033, natalizumab, Edaravone Injection, Desmoteplase, natalizumab, DLBS1033, MCI-186, and others
• The Acute Ischemic Stroke epidemiology based on gender analyzed that men are at higher risk for Acute Ischemic Stroke than women
• The Acute Ischemic Stroke market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Ischemic Stroke pipeline products will significantly revolutionize the Acute Ischemic Stroke market dynamics.

Acute Ischemic Stroke Overview

When a clot-like accumulation of thickened blood blocks blood flow via a brain artery, it causes an acute ischemic stroke (AIS). Depending on where they form within the body, clots are either thrombotic or embolic. The more frequent of the two stroke types, a thrombotic stroke, happens when a clot develops within a brain artery.

Get a Free sample for the Acute Ischemic Stroke Market Report 

https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market

Acute Ischemic Stroke Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Ischemic Stroke Epidemiology Segmentation:

The Acute Ischemic Stroke market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Acute Ischemic Stroke
• Prevalent Cases of Acute Ischemic Stroke by severity
• Gender-specific Prevalence of Acute Ischemic Stroke
• Diagnosed Cases of Episodic and Chronic Acute Ischemic Stroke

Download the report to understand which factors are driving Acute Ischemic Stroke epidemiology trends @ Acute Ischemic Stroke Epidemiology Forecast

Acute Ischemic Stroke Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Ischemic Stroke market or expected to get launched during the study period. The analysis covers Acute Ischemic Stroke market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Ischemic Stroke Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Ischemic Stroke Therapies and Key Companies

• MultiStem: Athersys/Healios K.K.
• Glenzocimab: Acticor Biotech
• LT-3001: Lumosa Therapeutics
• Elezanumab: Abbvie
• Intravenous glenzocimab (ACT017): Acticor Biotech
• Tirofiban: GrandPharma
• YM872 (zonampanel): Astellas Pharma
• Elezanumab: AbbVie
• rhPro-UK: Tasly Biopharmaceuticals
• LT3001: Shanghai Pharmaceuticals
• Balovaptan: Hoffmann-La Roche
• Alteplase: Tasly Biopharmaceuticals
• DLBS1033: Dexa Medica Group
• natalizumab: Biogen
• Edaravone Injection: Jiangsu Simcere
• Desmoteplase: Lundbeck
• natalizumab: Biogen
• DLBS1033: Dexa Medica Group
• MCI-186: Mitsubishi Tanabe Pharma

Discover more about therapies set to grab major Acute Ischemic Stroke market share @ Acute Ischemic Stroke Treatment Market

Acute Ischemic Stroke Market Drivers

• Increasing research and development to understand the diversity of the disease might improve the diagnosis of Acute Ischemic Stroke thereby resulting in a lucrative market opportunity
• Current treatments are used in relieving the symptoms and improving the quality of life of the patients

Acute Ischemic Stroke Market Barriers

• Several organizations are actively working to provide information and increase awareness of such diseases
• There are less treatment options for Acute Ischemic Stroke which opens a platform of new therapies to boost the market of Acute Ischemic Stroke

Scope of the Acute Ischemic Stroke Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acute Ischemic Stroke Companies: Athersys/Healios K.K., Acticor Biotech, Lumosa Therapeutics, Abbvie, Acticor Biotech, GrandPharma, Astellas Pharma, Tasly Biopharmaceuticals, Shanghai Pharmaceuticals, Hoffmann-La Roche, Biogen, Jiangsu Simcere, Lundbeck, Biogen, Dexa Medica Group, Mitsubishi Tanabe Pharma, and others
• Key Acute Ischemic Stroke Therapies: MultiStem, Glenzocimab, LT-3001, Elezanumab, Intravenous glenzocimab (ACT017), Tirofiban, YM872 (zonampanel), Elezanumab, rhPro-UK, LT3001, Balovaptan, Alteplase, DLBS1033, natalizumab, Edaravone Injection, Desmoteplase, natalizumab, DLBS1033, MCI-186, and others
• Acute Ischemic Stroke Therapeutic Assessment: Acute Ischemic Stroke current marketed and Acute Ischemic Stroke emerging therapies
• Acute Ischemic Stroke Market Dynamics: Acute Ischemic Stroke market drivers and Acute Ischemic Stroke market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Acute Ischemic Stroke Unmet Needs, KOL’s views, Analyst’s views, Acute Ischemic Stroke Market Access and Reimbursement 

To know more about Acute Ischemic Stroke companies working in the treatment market, visit @ Acute Ischemic Stroke Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Acute Ischemic Stroke Market Report Introduction

2. Executive Summary for Acute Ischemic Stroke

3. SWOT analysis of Acute Ischemic Stroke

4. Acute Ischemic Stroke Patient Share (%) Overview at a Glance

5. Acute Ischemic Stroke Market Overview at a Glance

6. Acute Ischemic Stroke Disease Background and Overview

7. Acute Ischemic Stroke Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Ischemic Stroke 

9. Acute Ischemic Stroke Current Treatment and Medical Practices

10. Acute Ischemic Stroke Unmet Needs

11. Acute Ischemic Stroke Emerging Therapies

12. Acute Ischemic Stroke Market Outlook

13. Country-Wise Acute Ischemic Stroke Market Analysis (2019–2032)

14. Acute Ischemic Stroke Market Access and Reimbursement of Therapies

15. Acute Ischemic Stroke Market Drivers

16. Acute Ischemic Stroke Market Barriers

17.  Acute Ischemic Stroke Appendix

18. Acute Ischemic Stroke Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services